ArticleBMC gastroenterology2025
Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveProgrammed death-1 (PD-1) inhibitors combined with chemotherapy show certain clinical benefits in advanced gastric cancer patients, but more evidence is still needed. The present study aimed to investigate the efficacy and safety of PD-1 inhibitors combined with chemotherapy in these patients.
methodsForty-three patients with advanced gastric cancer receiving PD-1 inhibitors (including camrelizumab, sintilimab, and tislelizumab, 200 mg every 3 weeks) combined with chemotherapy were retrospectively enrolled. Data on treatment response, progression-free survival (PFS), and adverse reactions were collected.
resultsThere were 1 (2.3%), 9 (20.9%), 32 (74.4%), and 1 (2.3%) patient who achieved complete response, partial response, stable disease, and progressive disease, respectively. The objective response rate and disease control rate were 23.3% and 97.7%. The 1- and 2-year cumulative PFS rates were 63.3% and 19.8%. The median PFS (95% confidence interval) was 13.5 (10.7–16.3) months. Higher Eastern Cooperative Oncology Group performance status score (per score) [hazard ratio (HR) = 5.404, P = 0.047] and higher maximum diameter of the lesion (per cm) (HR = 1.860, P = 0.048) independently predicted shorter PFS. The adverse reactions included hemoglobin decreased (76.7%; grade 3: 16.3%), white blood cells decreased (74.4%; grade 3: 7.0%), blood platelet decreased (25.6%; grade 3: 2.3%), white blood cells increased (9.3%; grade 3: none), and reactive cutaneous capillary endothelial proliferation (23.3%; grade 3: 2.3%).
conclusionPD-1 inhibitors combined with chemotherapy may be an optional regimen for patients with advanced gastric cancer. However, the retrospective design and small sample size may limit the generalizability and robustness of our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.